Search

Your search keyword '"Xu, Xiaohan"' showing total 7 results
Start Over Author "Xu, Xiaohan" Journal angiology
7 results on '"Xu, Xiaohan"'

3. Percutaneous Coronary Intervention Rates and Associated Independent Predictors for Progression of Nontarget Lesions in Patients With Diabetes Mellitus After Drug-Eluting Stent Implantation

Author

Wang, Le, primary, Zhou, Yujie, additional, Peng, Pingan, additional, Xu, Xiaohan, additional, Yang, Shiwei, additional, Liu, Wei, additional, Han, Hongya, additional, Jia, Dean, additional, Wang, Jianlong, additional, Ji, Qingwei, additional, Ge, Hailong, additional, Liu, Yuyang, additional, Shi, Dongmei, additional, and Zhao, Yingxin, additional

Published
2015
Full Text
View/download PDF

5. Percutaneous Coronary Intervention Rates and Associated Independent Predictors for Progression of Nontarget Lesions in Patients With Diabetes Mellitus After Drug-Eluting Stent Implantation.

Author

Wang, Le, Zhou, Yujie, Peng, Pingan, Xu, Xiaohan, Yang, Shiwei, Liu, Wei, Han, Hongya, Jia, Dean, Wang, Jianlong, Ji, Qingwei, Ge, Hailong, Liu, Yuyang, Shi, Dongmei, and Zhao, Yingxin

Subjects
CORONARY heart disease surgery, DIABETES complications, CHI-squared test, CONFIDENCE intervals, CORONARY disease, FISHER exact test, LOW density lipoproteins, MYOCARDIAL revascularization, REOPERATION, RESEARCH funding, T-test (Statistics), TRANSLUMINAL angioplasty, MULTIPLE regression analysis, RETROSPECTIVE studies, DISEASE progression, REVASCULARIZATION (Surgery), DATA analysis software, DRUG-eluting stents, DESCRIPTIVE statistics, ODDS ratio, MANN Whitney U Test
Abstract

Little is known about clinically driven percutaneous coronary intervention (PCI) rates and predictors for progression of nontarget lesions in diabetic patients who have undergone drug-eluting stent (DES) implantation. We retrospectively analyzed the clinical and angiographic data of 2187 diabetic patients undergoing DES implantation. The cumulative rate of nontarget lesion PCI was 6.3% at 1 year, 14.3% at 2 years, and 19.8% at 3 years. The independent predictors of need for clinically driven PCI in patients with diabetes mellitus after DES implantation included obesity (odds ratio [OR] 2.303, 95% confidence interval [CI] 1.657-3.199, P < .001), low levels of high-density lipoprotein cholesterol (OR 1.412, 95% CI 1.114-1.789, P = .004), statin use (OR 0.669, 95% CI 0.454-0.986, P = .042), insulin use (OR 1.310, 95% CI 1.030-1.665, P = .027), and Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score (OR 1.061, 95% CI 1.045-1.077, P < .001) at baseline PCI. These findings may facilitate prediction of the risk of repeat revascularization and improve repeat revascularization rates in diabetic patients after DES implantation. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

7. Rapamycin affects tissue plasminogen activator and plasminogen activator inhibitor I expression: a potential prothrombotic mechanism of drug-eluting stents.

Author

Ma Q, Zhou Y, Nie X, Yu M, Gao F, Wang Z, Ge H, Jia D, Yang S, Liu X, Han H, Hu B, Shen H, and Xu X

Subjects
Cells, Cultured, Dose-Response Relationship, Drug, Down-Regulation, Human Umbilical Vein Endothelial Cells metabolism, Humans, Plasminogen Activator Inhibitor 1 genetics, Prosthesis Design, RNA, Messenger metabolism, Thrombosis genetics, Thrombosis metabolism, Time Factors, Tissue Plasminogen Activator genetics, Up-Regulation, Cardiovascular Agents toxicity, Drug-Eluting Stents, Human Umbilical Vein Endothelial Cells drug effects, Plasminogen Activator Inhibitor 1 metabolism, Sirolimus toxicity, Thrombosis chemically induced, Tissue Plasminogen Activator metabolism
Abstract

Although drug-eluting stents (DESs) can decrease the risk of restenosis, this benefit is tempered by a possible increased risk of in-stent thrombosis. We assessed the effects of rapamycin on human umbilical vein endothelial cells (HUVECs) to identify the alterations in gene expression associated with thrombosis. Expression of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) was assessed in HUVECs treated with rapamycin (final concentrations: 1, 10, 100, and 1000 ng/mL) for 24 and 48 hours. Incubation of HUVECs with rapamycin strongly reduced the expression of t-PA in a concentration-dependant manner (P < .05 to < .01). However, the expression of PAI-1 was induced by rapamycin (P < .05 to < .01). The increase in PAI-1 induction was up to 3.3-fold. In conclusion, rapamycin inhibited t-PA and induced PAI-1 expression in HUVECs. This effect may contribute to in-stent thrombosis associated with DESs.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results